Children use canonical sentence schemas: A crosslinguistic study of word order and inflections

D. Slobin,T. Bever

DOI: https://doi.org/10.1016/0010-0277(82)90033-6

IF: 4.011

1982-12-31

Cognition

Abstract:

What problem does this paper attempt to address?

Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV.

R. Peebles,J. Sheller,R. Collins,K. Jarzecka,D. Mitchell,B. Graham

DOI: https://doi.org/10.1086/315783

2000-09-01

Abstract:Respiratory syncytial virus (RSV)-induced disease is associated with recurrent episodes of wheezing in children, and an effective vaccine currently is not available. The use of 2 immunizations (a formalin-inactivated, alum-precipitated RSV vaccine [FI-RSV] given intramuscularly and live RSV given intranasally [LVIN]), with a control immunization, were compared in a well-characterized model of RSV challenge, with or without concomitant allergic sensitization with ovalbumin. FI-RSV caused a significant increase in airway hyperresponsiveness in mice after RSV infection during allergic sensitization, and this was associated with an increase in type 2 cytokine production. In contrast, immunization with LVIN did not change type 2 cytokine production and protected against RSV-induced airway hyperresponsiveness in the setting of allergic sensitization. This study suggests that immune modulation with RSV vaccination can have profound effects on RSV-induced airway disease and that prevention of airway hyperresponsiveness is an important end point in vaccine development.
Viral vectors for gene delivery to the central nervous system

Selene Ingusci,Bonnie L Hall,William F Goins,Justus B Cohen,Joseph C Glorioso

DOI: https://doi.org/10.1016/B978-0-323-90120-8.00001-0

Abstract:Brain diseases with a known or suspected genetic basis represent an important frontier for advanced therapeutics. The central nervous system (CNS) is an intricate network in which diverse cell types with multiple functions communicate via complex signaling pathways, making therapeutic intervention in brain-related diseases challenging. Nevertheless, as more information on the molecular genetics of brain-related diseases becomes available, genetic intervention using gene therapeutic strategies should become more feasible. There remain, however, several significant hurdles to overcome that relate to (i) the development of appropriate gene vectors and (ii) methods to achieve local or broad vector delivery. Clearly, gene delivery tools must be engineered for distribution to the correct cell type in a specific brain region and to accomplish therapeutic transgene expression at an appropriate level and duration. They also must avoid all toxicity, including the induction of inflammatory responses. Over the last 40 years, various types of viral vectors have been developed as tools to introduce therapeutic genes into the brain, primarily targeting neurons. This review describes the most prominent vector systems currently approaching clinical application for CNS disorders and highlights both remaining challenges as well as improvements in vector designs that achieve greater safety, defined tropism, and therapeutic gene expression.
Viral Approaches to Study the Mammalian Brain: Lineage Tracing, Circuit Dissection and Therapeutic Applications

Wei Cong,Yun Shi,Yanqing Qi,Jinyun Wu,Ling Gong,Miao He

DOI: https://doi.org/10.1016/j.jneumeth.2020.108629

IF: 2.987

2020-01-01

Journal of Neuroscience Methods

Abstract:•Recombinant viruses are powerful tools for gene delivery to the nervous system.•Different research and therapeutic applications call for different viral features.•Barcoded viral libraries support multiplex lineage and axonal tracing.•Rapid expanding viral toolkit facilitates basic and translational researches.
Viral Tools for Neural Circuit Tracing

Qing Liu,Yang Wu,Huadong Wang,Fan Jia,Fuqiang Xu

DOI: https://doi.org/10.1007/s12264-022-00949-z

Abstract:Neural circuits provide an anatomical basis for functional networks. Therefore, dissecting the structure of neural circuits is essential to understanding how the brain works. Recombinant neurotropic viruses are important tools for neural circuit tracing with many advantages over non-viral tracers: they allow for anterograde, retrograde, and trans-synaptic delivery of tracers in a cell type-specific, circuit-selective manner. In this review, we summarize the recent developments in the viral tools for neural circuit tracing, discuss the key principles of using viral tools in neuroscience research, and highlight innovations for developing and optimizing viral tools for neural circuit tracing across diverse animal species, including nonhuman primates.
Adeno-associated virus vector delivery to the brain: Technology advancements and clinical applications

Dezhuang Ye,Chinwendu Chukwu,Yaoheng Yang,Zhongtao Hu,Hong Chen

DOI: https://doi.org/10.1016/j.addr.2024.115363

Abstract:Adeno-associated virus (AAV) vectors have emerged as a promising tool in the development of gene therapies for various neurological diseases, including Alzheimer's disease and Parkinson's disease. However, the blood-brain barrier (BBB) poses a significant challenge to successfully delivering AAV vectors to the brain. Strategies that can overcome the BBB to improve the AAV delivery efficiency to the brain are essential to successful brain-targeted gene therapy. This review provides an overview of existing strategies employed for AAV delivery to the brain, including direct intraparenchymal injection, intra-cerebral spinal fluid injection, intranasal delivery, and intravenous injection of BBB-permeable AAVs. Focused ultrasound has emerged as a promising technology for the noninvasive and spatially targeted delivery of AAV administered by intravenous injection. This review also summarizes each strategy's current preclinical and clinical applications in treating neurological diseases. Moreover, this review includes a detailed discussion of the recent advances in the emerging focused ultrasound-mediated AAV delivery. Understanding the state-of-the-art of these gene delivery approaches is critical for future technology development to fulfill the great promise of AAV in neurological disease treatment.
Tunneling asymmetry in high-Tc cuprates: Possible evidence for a submerged band with nondegenerate fermions.

Levín,Quader

Abstract:
Neurosurgical gene therapy for central nervous system diseases

Ruchit V Patel,Pranav Nanda,R Mark Richardson

DOI: https://doi.org/10.1016/j.neurot.2024.e00434

IF: 6.088

2024-08-26

Neurotherapeutics

Abstract:Viral vector mediated gene therapies for neurodegenerative and neurodevelopmental conditions that require neurosurgical administration continue to expand. We systematically reviewed the National Institutes of Health (NIH) ClinicalTrials.gov database to identify all clinical trials studying in-vivo viral vector mediated gene therapies targeted to the CNS for neurodegenerative and neurodevelopmental diseases. We isolated studies which delivered therapies using neurosurgical approaches: intracisternal, intraventricular, and/or intraparenchymal. Clinical trials primarily registered in international countries were included if they were referenced by an NIH registered clinical trial. We performed a scoping review to identify the preclinical studies that supported each human clinical trial. Key preclinical and clinical data were aggregated to characterize vector capsid design, delivery methods, gene expression profile, and clinical benefit. A total of 64 clinical trials were identified in active, completed, terminated, and long-term follow-up stages. A range of CNS conditions across pediatric and adult populations are being studied with CNS targeted viral vector gene therapy, including Alzheimer's disease, Parkinson's disease, AADC deficiency, sphingolipidoses, mucopolysaccharidoses, neuronal ceroid lipofuscinoses, spinal muscular atrophy, adrenoleukodystrophy, Canavan disease, frontotemporal dementia, Huntington's disease, Rett syndrome, Dravet syndrome, mesial temporal lobe epilepsy, and glutaric acidemia. Adeno-associated viral vectors (AAVs) were utilized by the majority of tested therapies, with vector serotypes, regulatory elements, delivery methods, and vector monitoring varying based on the disease being studied. Intraparenchymal delivery has evolved significantly, with MRI-guided convection-enhanced delivery established as a gold standard method for pioneering novel gene targets.
Unlocking the potential of adeno-associated virus in neuroscience: a brief review

DOI: https://doi.org/10.1007/s11033-024-09521-6

IF: 2.7422

2024-04-23

Molecular Biology Reports

Abstract:Adeno-associated virus (AAV) has emerged as a pivotal tool in neuroscience research, owing to its remarkable versatility and efficiency in delivering genetic material to diverse cell types within the nervous system. This mini review aims to underscore the advanced applications of AAV vectors in neuroscience and their profound potential to revolutionize our understanding of brain function and therapeutic interventions for neurological disorders. By providing a concise overview of the latest developments and strategies employing AAV vectors, this review illuminates the transformative role of AAV technology in unraveling the complexities of neural circuits and paving the way for innovative treatments. Through elucidating the multifaceted capabilities of AAV-mediated gene delivery, this review underscores its pivotal role as a cornerstone in contemporary neuroscience research, promising remarkable insights into the intricacies of brain biology and offering new avenues for therapeutic intervention.

biochemistry & molecular biology
The Glymphatic System Delivery Enhances the Transduction Efficiency of AAV1 to Brain Endothelial Cells in Adult Mice.

Gang Wu,Quan Jiang,Tiantian Cui,Xiuxiu Liu,Dongmei Gong,Yixuan Yin,Chengkun Wang,Tiantian Wang,YingMei Lu,Danyan Zhu,Feng Han

DOI: https://doi.org/10.1016/j.jneumeth.2019.108441

IF: 2.987

2019-01-01

Journal of Neuroscience Methods

Abstract:BACKGROUND:Recombinant adeno-associated virus (rAAV) is increasingly applied in neuroscience research or gene therapy. However, there is no simple and efficient tool for specific transfection of rAAV into cerebrovascular tissues. It has been reported that fluorescent tracers or beta-amyloid protein can enter the brain through perivascular spaces, named as "glymphatic system". The purpose of this study was to explore whether rAAV could transduce the cerebral vasculature through the glymphatic pathway.NEW METHOD:An AAV1-GFP vector suspension (15 μL) was injected into the intracisternal space of anesthetized mice (n = 2) and 5 μl was injected into the bulbus medullae (n = 2). As controls, 15 μl of artificial cerebrospinal fluid (aCSF) was injected into the cisterna magna. The endothelial specific transduction was verified by Glut1 or PDGFRβ immunofluorescent staining. Immunofluorescence images for all groups were captured with a laser microscope.RESULTS:It was observed that infection with rAAV1 vectors encoding green fluorescence protein resulted in a successful cerebrovascular transduction when injected into cisterna magna, compared to aCSF or intra-parenchymal injection at 30 days post-transduction in adult mice. In addition, GFP was co-localized with Glut1 based on immuno-fluorescence. These results indicate that glymphatic system delivery enhances the transduction efficiency of AAV1 to brain endothelial cells.COMPARISON WITH EXISTING METHODS:The AAV1 vector can simply and efficiently transduce the cerebral endothelial cells through the glymphatic pathway.CONCLUSION:The findings of this study reveal that rAAV1-based vectors have high application potential for endothelial-targeted neurologic disease research or gene-based therapies.
Lighting Up Neural Circuits by Viral Tracing

Liyao Qiu,Bin Zhang,Zhihua Gao

DOI: https://doi.org/10.1007/s12264-022-00860-7

IF: 5.271

2022-05-17

Neuroscience Bulletin

Abstract:Neurons are highly interwoven to form intricate neural circuits that underlie the diverse functions of the brain. Dissecting the anatomical organization of neural circuits is key to deciphering how the brain processes information, produces thoughts, and instructs behaviors. Over the past decades, recombinant viral vectors have become the most commonly used tracing tools to define circuit architecture. In this review, we introduce the current categories of viral tools and their proper application in circuit tracing. We further discuss some advances in viral tracing strategy and prospective innovations of viral tools for future study.

neurosciences
Modes of Admission to Hospital: A Survey of Emergency Admissions to a General Medical Unit

A. Patel

DOI: https://doi.org/10.1136/BMJ.1.5743.281

1971-01-30

British Medical Journal

Abstract:In a survey of the modes of referral and disposal of “acute patients” to a general medical unit during the period 1 February 1968 to 31 July 1970 only 1,432 out of 3,455 were referred by general practitioners. There was a high incidence of self-referral to hospital, and this trend was on the increase. A large percentage of self-referred patients came from their homes, and 65-77% of these arrived by ambulance ordered by themselves.
Optimization of lentiviral vectors generation for biomedical and clinical research purposes: contemporary trends in technology development and applications

Pankaj Kumar,Chan Woon-Khiong

DOI: https://doi.org/10.2174/156652311794940782

Abstract:Classical non-viral methods of gene transfer, such as chemical transfection, have met with limited success of instillation of genetic material into non-proliferating cells in vitro. Among the different kinds of viral vectors, Lentiviral vectors (LVs) have emerged as robust and versatile tool for ex vivo and in vivo gene delivery into multiple cell types including non-dividing cells such as neurons. The capacity of LVs to maintain stable, long-term transgene expression and the substantial flexibility in the design of the expression cassettes account for their increasing use in various pre-clinical and clinical applications. Additionally, LVs have been hugely successful in reprogramming induced pluripotent stem cells (iPSCs). Recent development using LVs in conjunction with a Cre-Lox based reversible system has opened up many new possibilities towards therapeutic application of iPSC technology in various clinical settings. Moreover, improvements in term of biosafety and efficacy, achieved either by modifying the vector design or by involving integration-deficient LVs (IDLVs), have important implications for adoption of LV as the vector of choice for clinical trials. Several human gene therapy clinical trials evaluating the use of LVs for treatment: of human diseases such as Parkinson's disease, β-thalassemia, X-linked adrenoleukodystrophy (ALD), and AIDS are currently ongoing. This review will describe the state of the art achieved by LV technology, its impact on biomedical research, and implications to human clinical trials as therapeutic gene delivery vehicle for a wide range of infectious and genetic diseases.
Targeting microglia with lentivirus and AAV: Recent advances and remaining challenges

Margaret E Maes,Gloria Colombo,Rouven Schulz,Sandra Siegert,Margaret E. Maes

DOI: https://doi.org/10.1016/j.neulet.2019.134310

IF: 3.197

2019-08-01

Neuroscience Letters

Abstract:Microglia have emerged as a critical component of neurodegenerative diseases. Genetic manipulation of microglia can elucidate their functional impact in disease. In neuroscience, recombinant viruses such as lentiviruses and adeno-associated viruses (AAVs) have been successfully used to target various cell types in the brain, although effective transduction of microglia is rare. In this review, we provide a short background of lentiviruses and AAVs, and strategies for designing recombinant viral vectors. Then, we will summarize recent literature on successful microglial transductions in vitro and in vivo, and discuss the current challenges. Finally, we provide guidelines for reporting the efficiency and specificity of viral targeting in microglia, which will enable the microglial research community to assess and improve methodologies for future studies.

neurosciences
Highly Effective Stroke Therapy Enabled by Genetically Engineered Viral Nanofibers

Xiangyu Liu,Mei Yang,Fang Lei,Yaru Wang,Mingying Yang,Chuanbin Mao

DOI: https://doi.org/10.1002/adma.202201210

IF: 29.4

2022-01-01

Advanced Materials

Abstract:Stroke results in the formation of a cavity in the infarcted brain tissue. Angiogenesis and neurogenesis are poor in the cavity, preventing brain-tissue regeneration for stroke therapy. To regenerate brain tissue in the cavity, filamentous phages, the human-safe nanofiber-like bacteria-specific viruses, are genetically engineered to display many copies of RGD peptide on the sidewalls. The viral nanofibers, electrostatically coated on biocompatible injectable silk protein microparticles, not only promote adhesion, proliferation, and infiltration of neural stem cells (NSCs), but also induce NSCs to differentiate preferentially into neurons in basal medium within 3 d. After the NSC-loaded microparticles are injected into the stroke cavity of rat models, the phage nanofibers on the microparticles stimulate angiogenesis and neurogenesis in the stroke sites within two weeks for brain regeneration, leading to functional recovery of limb motor control of rats within 12 weeks. The viral nanofibers also brought about the desired outcomes for stroke therapy, such as reducing inflammatory response, decreasing thickness of astrocytes scars, and increasing neuroblasts response in the subventricular zone. As virtually any functional peptide can be displayed on the phage by genetic means, the phage nanofibers hold promise as a unique and effective injectable biomaterial for stroke therapy.
Enhanced AAV transduction across preclinical CNS models: A comparative study in human brain organoids with cross-species evaluations

Matthieu Drouyer,Jessica Merjane,Teodora Nedelkoska,Adrian Westhaus,Suzanne Scott,Scott Lee,Peter G.R. Burke,Simon McMullan,Jose L. Lanciego,Ana F. Vicente,Ricardo Bugallo,Carmen Unzu,Gloria González-Aseguinolaza,Anai Gonzalez-Cordero,Leszek Lisowski

DOI: https://doi.org/10.1016/j.omtn.2024.102264

IF: 10.183

2024-07-13

Molecular Therapy — Nucleic Acids

Abstract:Viral vectors based on recombinant adeno-associated virus (rAAV) have become the most widely used system for therapeutic gene delivery in the central nervous system (CNS). Despite clinical safety and efficacy in neurological applications, a barrier to adoption of the current generation of vectors lies in their limited efficiency, resulting in limited transduction of CNS target cells. To address this limitation, researchers have bioengineered fit-for-purpose AAVs with improved CNS tropism and tissue penetration. While the preclinical assessment of these novel AAVs is primarily conducted in animal models, human induced pluripotent stem cell (hiPSC)-derived organoids offer a unique opportunity to functionally evaluate novel AAV variants in a human context. In this study, we performed a comprehensive and unbiased evaluation of a large number of wild-type and bioengineered AAV capsids for their transduction efficiency in hiPSC-derived brain organoids. We demonstrate that efficient AAV transduction observed in organoids was recapitulated in vivo in both mouse and non-human primate models after cerebrospinal fluid (CSF) delivery. In summary, our study showcases the use of brain organoid systems for the pre-screening of novel AAV vectors. Additionally, we report data for novel AAV variants that exhibit improved CNS transduction efficiency when delivered via the CSF in in vivo preclinical models.

medicine, research & experimental
Tip30 deletion in MMTV-Neu mice leads to enhanced EGFR signaling and development of estrogen receptor-positive and progesterone receptor-negative mammary tumors.

Chengliang Zhang,M. Mori,Sheng-lan Gao,Aimin Li,Isamu Hoshino,Mark D. Aupperlee,S. Haslam,Hua Xiao

DOI: https://doi.org/10.1158/0008-5472.CAN-10-3057

IF: 11.2

2010-12-15

Cancer Research

Abstract:Estrogen receptor-positive and progesterone receptor-negative (ER+/PR-) breast cancers account for 15% to 25% of all human breast cancers and display more aggressive malignant characteristics than ER+/PR+ cancers. However, the molecular mechanism underlying development of ER+/PR- breast cancers still remains elusive. We show here that Tip30 deletion dramatically accelerated the onset of mammary tumors in the MMTV-Neu mouse model of breast cancer. The mammary tumors arising in Tip30(-/-)/MMTV-Neu mice were exclusively ER+/PR-. The growth of these ER+/PR- tumors depends not only on estrogen but also on progesterone despite the absence of detectable PR. Tip30 is predominantly expressed in ER+ mammary epithelial cells, and its deletion leads to an increase in the number of phospho-ERα-positive cells in mammary glands and accelerated activation of Akt in MMTV-Neu mice. Moreover, we found that Tip30 regulates the EGFR pathway through controlling endocytic downregulation of EGFR protein level and signaling. Together, these findings suggest a novel mechanism in which loss of Tip30 cooperates with Neu activation to enhance the activation of Akt signaling, leading to the development of ER+/PR- mammary tumors.
The work rate corresponding to ventilatory threshold during steady-state and ramp exercise.

O. Faude,T. Meyer,W. Kindermann

DOI: https://doi.org/10.1123/IJSPP.1.3.222

IF: 4.211

2006-09-01

International Journal of Sports Physiology and Performance

Abstract:PURPOSE The work rate (WR) corresponding to ventilatory threshold (VT) is an appropriate intensity for regenerative and low-intensity training sessions. During incremental ramp exercise, VO(2) increase lags behind WR increase. Traditionally, a VO(2) time delay (t(d)) of 45 seconds is used to calculate the WR at VT from such tests. Considerable inaccuracies were observed when using this constant td. Therefore, this study aimed at reinvestigating the temporal relationship between VO(2) and WR at VT. METHODS 20 subjects (VO(2peak) 49.9 to 72.6 mL x min-1 x kg-1) performed a ramp test in order to determine VT and a subsequent steady-state test during which WR was adjusted to elicit the VO(2) corresponding to VT. The difference in WR and heart rate at VT was calculated between the ramp and the steady-state test (WR(diff), HR(diff)) as well as the time delay corresponding to WR(diff) during ramp exercise. RESULTS Mean values were td = 85 + or - 26 seconds (range 38 to 144), WR(diff) = 45 + or - 12 W (range 23 to 67), HR(diff) = 1 + or - 9 beats/min (range -21 to +15). The limits of agreement for the difference between WR at VT during ramp and steady-state exercise were + or - 24 W. No significant influence on td, WR(diff), or HR(diff) from differences in endurance capacity (VO(2peak) and VT; P > .10 for all correlations) or ramp increment (P = .26, .49, and .85, respectively) were observed. CONCLUSION The wide ranges of td, WR(diff), and HR(diff) prevent the derivation of exact training guidelines from single-ramp tests. It is advisable to perform a steady-state test to exactly determine the WR corresponding to VT.
Common AAV gene therapy vectors show indiscriminate transduction of living human brain cell types

JP McGinnis,Joshua Ortiz-Guzman,Maria Camila Guevara,Sai Mallannagari,Benjamin DW Belfort,Suyang Bao,Snighda Srivastava,Maria Morkas,Emily Ji,Angela Addison,Evelyne Tantry,Sarah Chen,Ying Wang,Zihong Chen,Kalman A. Katlowitz,Jeffrey J. Lange,Melissa Blessing,Carrie Mohila,M. Cecilia Ljungberg,Guillermo Aldave,Ali Jalali,Akash Patel,Sameer Sheth,Howard L. Weiner,Shankar Gopinath,Ganesh Rao,Akdes Serin-Harmanci,Daniel Curry,Benjamin Arenkiel

DOI: https://doi.org/10.1101/2024.11.14.623624

2024-11-15

Abstract:The development of cell-type-specific gene therapy vectors for treating neurological diseases holds great promise, but has relied on animal models with limited translational utility. We have adapted an ex vivo organotypic model to evaluate adeno-associated virus (AAV) transduction properties in living slices of human brain tissue. Using fluorescent reporter expression and single-nucleus RNA sequencing, we found that common AAV vectors show broad transduction of normal cell types, with protein expression most apparent in astrocytes; this work introduces a pipeline for identifying and optimizing AAV gene therapy vectors in human brain samples.

Bioengineering
Functional gene delivery to and across brain vasculature of systemic AAVs with endothelial-specific tropism in rodents and broad tropism in primates

Xinhong Chen,Damien A Wolfe,Dhanesh Sivadasan Bindu,Mengying Zhang,Naz Taskin,David Goertsen,Timothy F Shay,Erin E Sullivan,Sheng-Fu Huang,Sripriya Ravindra Kumar,Cynthia M Arokiaraj,Viktor M Plattner,Lillian J Campos,John K Mich,Deja Monet,Victoria Ngo,Xiaozhe Ding,Victoria Omstead,Natalie Weed,Yeme Bishaw,Bryan B Gore,Ed S Lein,Athena Akrami,Cory Miller,Boaz P Levi,Annika Keller,Jonathan T Ting,Andrew S Fox,Cagla Eroglu,Viviana Gradinaru

DOI: https://doi.org/10.1038/s41467-023-38582-7

2023-06-08

Abstract:Delivering genes to and across the brain vasculature efficiently and specifically across species remains a critical challenge for addressing neurological diseases. We have evolved adeno-associated virus (AAV9) capsids into vectors that transduce brain endothelial cells specifically and efficiently following systemic administration in wild-type mice with diverse genetic backgrounds, and in rats. These AAVs also exhibit superior transduction of the CNS across non-human primates (marmosets and rhesus macaques), and in ex vivo human brain slices, although the endothelial tropism is not conserved across species. The capsid modifications translate from AAV9 to other serotypes such as AAV1 and AAV-DJ, enabling serotype switching for sequential AAV administration in mice. We demonstrate that the endothelial-specific mouse capsids can be used to genetically engineer the blood-brain barrier by transforming the mouse brain vasculature into a functional biofactory. We apply this approach to Hevin knockout mice, where AAV-X1-mediated ectopic expression of the synaptogenic protein Sparcl1/Hevin in brain endothelial cells rescued synaptic deficits.
Vesicular stomatitis virus enables gene transfer and transsynaptic tracing in a wide range of organisms

Nathan A. Mundell,Kevin T. Beier,Y. Albert Pan,Sylvain W. Lapan,Didem Göz Aytürk,Vladimir K. Berezovskii,Abigail R. Wark,Eugene Drokhlyansky,Jan Bielecki,Richard T. Born,Alexander F. Schier,Constance L. Cepko

DOI: https://doi.org/10.1002/cne.23761

2015-04-02

Abstract:Current limitations in technology have prevented an extensive analysis of the connections among neurons, particularly within nonmammalian organisms. We developed a transsynaptic viral tracer originally for use in mice, and then tested its utility in a broader range of organisms. By engineering the vesicular stomatitis virus (VSV) to encode a fluorophore and either the rabies virus glycoprotein (RABV-G) or its own glycoprotein (VSV-G), we created viruses that can transsynaptically label neuronal circuits in either the retrograde or anterograde direction, respectively. The vectors were investigated for their utility as polysynaptic tracers of chicken and zebrafish visual pathways. They showed patterns of connectivity consistent with previously characterized visual system connections, and revealed several potentially novel connections. Further, these vectors were shown to infect neurons in several other vertebrates, including Old and New World monkeys, seahorses, axolotls, and Xenopus. They were also shown to infect two invertebrates, Drosophila melanogaster, and the box jellyfish, Tripedalia cystophora, a species previously intractable for gene transfer, although no clear evidence of transsynaptic spread was observed in these species. These vectors provide a starting point for transsynaptic tracing in most vertebrates, and are also excellent candidates for gene transfer in organisms that have been refractory to other methods.

neurosciences,zoology

Children use canonical sentence schemas: A crosslinguistic study of word order and inflections

Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV.

Viral vectors for gene delivery to the central nervous system

Viral Approaches to Study the Mammalian Brain: Lineage Tracing, Circuit Dissection and Therapeutic Applications

Viral Tools for Neural Circuit Tracing

Adeno-associated virus vector delivery to the brain: Technology advancements and clinical applications

Tunneling asymmetry in high-Tc cuprates: Possible evidence for a submerged band with nondegenerate fermions.

Neurosurgical gene therapy for central nervous system diseases

Unlocking the potential of adeno-associated virus in neuroscience: a brief review

The Glymphatic System Delivery Enhances the Transduction Efficiency of AAV1 to Brain Endothelial Cells in Adult Mice.

Lighting Up Neural Circuits by Viral Tracing

Modes of Admission to Hospital: A Survey of Emergency Admissions to a General Medical Unit

Optimization of lentiviral vectors generation for biomedical and clinical research purposes: contemporary trends in technology development and applications

Targeting microglia with lentivirus and AAV: Recent advances and remaining challenges

Highly Effective Stroke Therapy Enabled by Genetically Engineered Viral Nanofibers

Enhanced AAV transduction across preclinical CNS models: A comparative study in human brain organoids with cross-species evaluations

Tip30 deletion in MMTV-Neu mice leads to enhanced EGFR signaling and development of estrogen receptor-positive and progesterone receptor-negative mammary tumors.

The work rate corresponding to ventilatory threshold during steady-state and ramp exercise.

Common AAV gene therapy vectors show indiscriminate transduction of living human brain cell types

Functional gene delivery to and across brain vasculature of systemic AAVs with endothelial-specific tropism in rodents and broad tropism in primates

Vesicular stomatitis virus enables gene transfer and transsynaptic tracing in a wide range of organisms